Abstract
The genus Cissampelos comprises of 21 species which have a wide global distribution and various pharmacological activities such as analgesic and antipyretic, antiinflammatory, anti-allergic, bronchodilation, and immunomodulation among others. Several compounds, mainly alkaloids with differing biological activities have been isolated from this genus. We will highlight antipyretic activities, anti-inflammatory, antiallergic, bronchodilatory, and immunomodulatory activities. In addition, we applied ligand-based-virtual screening associated with structure-based-virtual screening of a small dataset of 63 secondary metabolites from the Cissampelos genus of an in-house data bank, in order to select compounds with potential anti-inflammatory activity. Affinities were observed for hayatine (26), isochondrondendrine (30), pelosine (52), sepeerine (59), and warifteine (63) to the inhibiting enzymes MAPK p38 alpha, PKC beta, PKC theta and PKC zeta. The cissampeloflavone compound (8) alone showed no potential inhibitory activity for PKC zeta, or affinity for the PKC alpha. The compounds can be used as starting points for further studies on structures with potential anti-inflammatory activity.
Keywords: Cissampelos, anti-inflammatory activity, virtual screening, multi-target, secondary metabolites, asthma.
Current Medicinal Chemistry
Title:Secondary Metabolites from Cissampelos, A Possible Source for New Leads with Anti-Inflammatory Activity
Volume: 24 Issue: 16
Author(s): Mateus F. Alves, Marcus T. Scotti, Luciana Scotti*, Francisco Jaime Bezerra Mendonça, José M. B. Filho, Sílvia A. L. de Melo, Sócrates G. dos Santos and Margareth de F.F.M. Diniz
Affiliation:
- Health Sciences Center, Federal University of Paraíba, Campus I, 58051-970, João Pessoa- PB,Brazil
Keywords: Cissampelos, anti-inflammatory activity, virtual screening, multi-target, secondary metabolites, asthma.
Abstract: The genus Cissampelos comprises of 21 species which have a wide global distribution and various pharmacological activities such as analgesic and antipyretic, antiinflammatory, anti-allergic, bronchodilation, and immunomodulation among others. Several compounds, mainly alkaloids with differing biological activities have been isolated from this genus. We will highlight antipyretic activities, anti-inflammatory, antiallergic, bronchodilatory, and immunomodulatory activities. In addition, we applied ligand-based-virtual screening associated with structure-based-virtual screening of a small dataset of 63 secondary metabolites from the Cissampelos genus of an in-house data bank, in order to select compounds with potential anti-inflammatory activity. Affinities were observed for hayatine (26), isochondrondendrine (30), pelosine (52), sepeerine (59), and warifteine (63) to the inhibiting enzymes MAPK p38 alpha, PKC beta, PKC theta and PKC zeta. The cissampeloflavone compound (8) alone showed no potential inhibitory activity for PKC zeta, or affinity for the PKC alpha. The compounds can be used as starting points for further studies on structures with potential anti-inflammatory activity.
Export Options
About this article
Cite this article as:
Alves F. Mateus, Scotti T. Marcus, Scotti Luciana*, Mendonça Jaime Bezerra Francisco, Filho M. B. José, de Melo A. L. Sílvia, dos Santos G. Sócrates and de F.F.M. Diniz Margareth, Secondary Metabolites from Cissampelos, A Possible Source for New Leads with Anti-Inflammatory Activity, Current Medicinal Chemistry 2017; 24 (16) . https://dx.doi.org/10.2174/0929867323666161227123411
DOI https://dx.doi.org/10.2174/0929867323666161227123411 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preliminary Pharmacological Screening of Some Thiosemicarbazide, s-triazole, and Thiadiazole Derivatives
CNS & Neurological Disorders - Drug Targets Tinea Capitis: An Updated Review
Recent Patents on Inflammation & Allergy Drug Discovery Azole Antimycotics - A Highway to New Drugs or a Dead End?
Current Medicinal Chemistry Stent Selection in Patients with Myocardial Infarction: Drug Eluting, Biodegradable Polymers or Bare Metal Stents?
Recent Patents on Cardiovascular Drug Discovery Longitudinal Molecular Imaging of Burn Wound Healing: Effect of Staphylococcus aureus, or Lack of Tumor Necrosis Factor (TNF) or Interleukin-6 (Il-6)
Current Molecular Imaging (Discontinued) The Apoptotic Pathway as a Therapeutic Target in Sepsis
Current Drug Targets Thyroglobulin Autoantibodies as Surrogate Biomarkers in the Management of Patients with Differentiated Thyroid Carcinoma
Current Medicinal Chemistry Resistance to Apoptosis: Mechanism for the Development of HIV Reservoirs
Current HIV Research Cancer Immunotherapy: An Effective Tool in Cancer Control and Treatment
Current Cancer Therapy Reviews N6-methyladenine RNA Modification (m<sup>6</sup>A): An Emerging Regulator of Metabolic Diseases
Current Drug Targets Current Perspectives on the Role of Nrf2 in 5-Fluorouracil Resistance in Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Interleukin-1 in the Treatment of Selected Cardiovascular Complications
Current Reviews in Clinical and Experimental Pharmacology <i>In Silico</i> Design of a Novel Multi-Epitope Peptide Vaccine Against Hepatocellular Carcinoma
Letters in Drug Design & Discovery AMPK: Therapeutic Target for Diabetes and Cancer Prevention
Current Pharmaceutical Design Editorial [Hot Topic: The Impact of Microbiota and Cytokines on Inflammatory Bowel Disease (Executive Editors: Osamu Kanauchi and Keiichi Mitsuyama)]
Current Pharmaceutical Design Allergic Asthma: A Summary from Genetic Basis, Mouse Studies, to Diagnosis and Treatment
Current Pharmaceutical Design Identifying Molecular Biomarker for the Lung Squamous Cell Carcinoma by Integrating Multifactorial Data
Current Bioinformatics Phase Transition System: Novel Oral In-Situ Gel
Current Drug Delivery Development ofNovel Compounds to Treat Autoimmune and Inflammatory Diseases and Graft Versus Host Reactions
Endocrine, Metabolic & Immune Disorders - Drug Targets Rifaximin: The Revolutionary Antibiotic Approach for Irritable Bowel Syndrome
Mini-Reviews in Medicinal Chemistry